Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.
Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).
An analysis of select responses to a survey conducted by researchers from the College of Nursing at South Dakota State University identified oncology nurses' comfort level in handling end-of-life care and patient education.
Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.
Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
In a prospective study, researchers assessed survival and quality of life measures for patients with advanced cancer in relation to where they are discharged from hospital: postacute care (PAC), hospice, or home without hospice.
Previous studies have shown that patients with advanced cancer may experience some financial relief integrating palliative care with standard oncologic care, but these results were coincidental findings and have not yet been fully explored.
WWW is not for the world-wide web, but it is an easy way to remember the 3 w's of communication with patients with advanced disease: wish, worry, wonder.
Investigators conducted a study involving more than 1000 patients with advanced cancer to assess the factors that contribute to prolonged hospital stays and increased risk for readmissions.
Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.
A smaller dose of cabazitaxel (C20) is noninferior to a larger dose (C25) in the post-docetaxel treatment of mCRPC.
Lorazepam plus haloperidol is more effective than haloperidol alone at reducing agitation, study finds.
Palliative radiotherapy for bone metastases is safe, effective — but controversy persists for single-fraction treatment.
Simply walking for 30 minutes 3 times a week has significant impact on symptom severity and ability to cope, as well as quality of life, for patients with advanced cancer.
There is no association between vasectomy and the risk of overall, high-grade, or advanced-stage prostate cancer or prostate cancer-related mortality.
Treatment expectations of individuals with metastatic prostate cancer and their health care providers often do not match.
Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.
A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.
Nearly half of patients with advanced cancer around the world believe they will be cured, with the perception of curability significantly differing by education, performance status, and country of origin.
Treatment with methylnaltrexone was associated with improved overall survival in patients with advanced cancer.
Despite the infrequency of urine drug test ordering, greater than half of all urine drug tests results were abnormal among outpatients with advanced cancer.
Increasing body mass index (BMI) allows growth and progression of disease in patients with multiple myeloma, a recently published study has shown.
Advanced Cancer Patients Often Unaware That They Are More Optimistic About Their Prognosis Than Their OncologistsJuly 27, 2016
Most patients with advanced cancer report far more optimistic expectations for survival prognosis than their oncologists because patients misunderstand their oncologists' clinical judgment.
MYL-1401O is comparable in efficacy and safety to the anti-HER2 monoclonal antibody trastuzumab as frontline therapy in breast cancer.
A Web application called Moovcare that guides follow-up improved survival for patients with advanced lung cancer after receiving initial therapy.
Patients participating in early-phase clinical trials should be assessed for sleep quality, as poor sleep quality is associated with greater fatigue, symptom burden, and mood disturbance.
Managing pain with opioids and keeping a close eye on adverse effects is an important part of cancer care. But there is room for improvement in pain management tools, and nurses play a key role in their evolution.
In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.
Immunotherapy for advanced ovarian cancer more effectively treats tumors when administered immediately after chemotherapy. Sequential chemoimmunotherapy could improve disease control in stage IIIC/IV tubo-ovarian HGSC.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|